Fig. 5. DAGs and PAs inhibit TREK currents. (A and B) Fifteen minute perfusion of 50 µM RHC80267 (rhc), a DAG lipase inhibitor, slows down the recovery of TREK currents without effect on TASK currents (black squares, first glutamate application in control conditions; white circles, second glutamate application during RHC80267 application). (C) Direct inhibition of TREK2 currents by 10 µM SAG in inside-out patch configuration. TREK2 currents are activated by 3 µM AA. (D) Time-course of TREK2 current inhibition by 10 µM SAG, SLG and diPGP. (E) Percent of inhibition of various DAGs and PAs and phosphoinositides in the presence of 3 mM internal Mg²⁺, on TREK1 (black bars) and TREK2 (white bars). *P < 0.01.